Recursion Pharmaceuticals, Inc. RXRX
Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX) is a GI/hepatology drug developer. Its lead program, REC-4881, is in Phase 2 for Familial adenomatous polyposis (FAP). Its next catalyst on record is REC-4881 (MEK1/2 inhibitor): Recursion expects an FDA update on REC-4881 in 2H 2026 regarding registrational trial pathway. (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: REC-4881 (MEK1/2 inhibitor) — Recursion expects an FDA update on REC-4881 in 2H 2026 regarding registrational trial pathway. (H2 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| REC-4881 | Familial adenomatous polyposis (FAP) | small molecule | Phase 2 |
| REC-1245 | Endometrial cancer and other solid tumors | small molecule | Phase 1 |
| REC-7735 | PIK3CA H1047R-mutant solid tumors | small molecule | Phase 1 |
| REC-4539 | Solid tumors and hematology | small molecule | Pre-clinical |
| REC-102 | Hypophosphatasia | small molecule | Pre-clinical |
| REC-617 | CDK7-related (indication not specified) | small molecule | Pre-clinical |
| REC-3565 | MALT1-related (indication not specified) | small molecule | Pre-clinical |
Recent results and decisions
- Nov 2, 2026positive REC-4881 showed deep, durable polyp burden reductions across the GI tract in FAP patients after 12 weeks of treatment, with activity persisting off treatment.
After 12 weeks of treatment, median polyp burden reductions were 55% in the upper GI and 50% in the lower GI, supporting REC-4881's potential as a single oral therapy to address FAP across the GI tract.
Filing - Oct 15, 2026positive Phase 1 dose escalation: 3 partial responses (2 confirmed) at 45 mg QD or higher in endometrial cancer and HCC, 91.7% disease control rate (n=12); 45 mg QD selected for expansion.
Three partial responses per RECIST 1.1 criteria (2 confirmed, 1 unconfirmed) in heavily pretreated patients with endometrial cancer and hepatocellular carcinoma, all at doses of 45 mg once daily (QD) or higher, with a disease control rate of 91.7% at those doses (n=12).
Filing - Oct 15, 2026positive REC-4881 Phase 1b/2 update shows 47% median reduction in total polyp burden and 55% median reduction in upper GI polyps, with 92% of patients responding in upper GI and durable reductions maintained 12 weeks off treatment.
87% of patients achieved reductions in total polyp burden, with a 47% median reduction in total polyp burden at week 13; In the upper GI tract, 92% of 13 evaluable patients experienced reductions, with 46% achieving equal to or greater than a 65% reduction.
Filing
10 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.